β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF
Related Experiment Video
Updated: May 21, 2026

Tracing Gene Expression Through Detection of β-galactosidase Activity in Whole Mouse Embryos
Published on: June 26, 2018
Yoshihiro Uto1, Syota Yamamoto, Hirotaka Mukai
1Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, 2-1 Minamijosanjimacho, Tokushima 770-8506, Japan. uto@bio.tokushima-u.ac.jp
Background:
The 1f1f subtype of the group-specific component (Gc) protein is converted into Gc protein-derived macrophage-activating factor (GcMAF) by enzymatic processing with β-galactosidase and sialidase. We previously demonstrated that preGc(1f1f)MAF, a full Gc(1f1f) protein otherwise lacking a galactosyl moiety, can be converted to GcMAF by treatment with mouse peritoneal fluid. Here, we investigated the effects of the β-galactosidase-treated 1s1s and 22 subtypes of Gc protein (preGc(1s1s)MAF and preGc₂₂MAF) on the phagocytic activation of mouse peritoneal macrophages.
Results:
We demonstrated the presence of Gal-GalNAc disaccharide sugar structures in the Gc(1s1s) protein by western blotting using peanut agglutinin and Helix pomatia agglutinin lectin. We also found that preGc(1s1s)MAF and preGc₂₂MAF significantly enhanced the phagocytic activity of mouse peritoneal macrophages in the presence and absence of mouse peritoneal fluid.
Conclusion:
We demonstrate that preGc(1s1s)MAF and preGc₂₂MAF proteins can be used as effective macrophage activators.
Related Concept Videos
Activation and Inactivation of G Proteins
Reporter Genes
Commonly used reporter...

